Wegovy HSE reimbursement gets NCPE backing with a €4.4 billion budget warning

Ireland's drug value watchdog has told the health service to consider paying for Wegovy, the first formal step toward Wegovy HSE reimbursement for people with obesity. The National Centre for Pharmacoeconomics found the drug cost effective but warned that the budget impact would be substantial, putting treatment for every eligible adult at €4.4 billion over five years. Nothing changes at the pharmacy yet. Here is what the advice says, what it would cost, and what happens next.

What the NCPE recommended

The NCPE completed its assessment of semaglutide, sold as Wegovy, on October 13, according to the timeline on its assessment page. Its conclusion is short: "The NCPE recommends that semaglutide (Wegovy®) be considered for reimbursement for the indication under assessment." That indication covers adults with a starting body mass index of 30 or more, and adults with a BMI from 27 to under 30 who have at least one weight related condition, such as prediabetes, type 2 diabetes, high blood pressure, abnormal blood fats, sleep apnoea or heart disease. The drug is used together with a reduced calorie diet and more physical activity. The centre added a warning in the same document: "Budget impact estimates associated with semaglutide are substantial."

The process took well over a year. The HSE asked for a rapid review in March 2025, and that review, finished in May 2025, called for a full health technology assessment. The HSE commissioned the full assessment at the end of May 2025, the company sent its full submission in February 2026, and the centre restarted its work twice before finishing in October. A recommendation of this kind is advice, not a decision on Wegovy HSE reimbursement. The NCPE judges value for money, while the HSE decides whether to pay and on what terms. The centre said affordability will have to be weighed when that decision is made, which leaves room for a narrow start.

The cost of Wegovy HSE reimbursement

The numbers explain the caution. Up to one million people in Ireland could benefit from treatment, and paying for all of them would cost €4.4 billion over five years, according to NCPE figures reported by TheJournal.ie. If the HSE limited access to people with a BMI over 40 and a weight related condition, the five year cost would fall to €265 million. Michael Barry, clinical director of the NCPE, told RTÉ Radio 1 that this scale puts weight loss drugs in a class of their own. He noted that other costly medicines, such as some cancer and rare disease drugs, might run to €20 million to €30 million over five years.

If the HSE limited access to people with a BMI over 40 and a weight related condition, the five year cost would fall to €265 million.

Per patient, the yearly drug cost used in the assessment was €2,918 at the standard maintenance strength and €4,370 at the newer higher strength, the Irish Medical Times reported. Barry said Wegovy was cost effective for every group the centre looked at, from people with a BMI between 27 and 30 to those above 40. It also came out as better value than Mounjaro, which produces more weight loss but was more expensive when the NCPE assessed it last December. The HSE Drugs Group has begun looking at whether Mounjaro should be funded for similar patients, according to the same report. That sets up a direct price contest between the two makers for any future public scheme.

What patients pay today and what could change

For now, Wegovy is a private purchase for most people in Ireland. Thousands already take GLP 1 drugs for obesity and pay for them themselves, at a cost of thousands of euro a year, TheJournal.ie reported. If Wegovy HSE reimbursement went ahead, two existing schemes would shape what patients pay. People with a medical card, who qualify through being over 70, on a lower income or by other criteria, are entitled to free medication. Under the Drugs Payment Scheme, which is not means tested, a family pays no more than €80 a month for drugs on the reimbursement list. Either route would cut the monthly bill sharply for the people who qualify.

One in five people in Ireland has obesity, according to government research cited by TheJournal.ie, so even a narrow scheme would reach a large group. Funding rules could also be tighter than the licence. The €265 million option shows how the HSE might begin with the most severe cases, which would leave many people who pay privately today outside any scheme. For prescribers, that would mean clear criteria and new paperwork. For pharmacies, a funded scheme would bring more prescriptions and a need for steady stock. None of this is settled, and patients now on private prescriptions should not expect any change to what they pay until the HSE makes its decision.

What happens next at the HSE

The HSE called the NCPE recommendation "nuanced" and said its approach to GLP 1 drugs raises important questions of health policy. It said the budget question will be talked through in the months ahead and that its corporate pharmaceutical unit will negotiate with the makers on price. The Irish Medical Times reported that several meetings are expected before a final recommendation goes to the HSE chief executive, Anne O'Connor. Barry told RTÉ that funding the drug would likely need a shift in health policy led by the Department of Health and the wider government. The timeline below shows how long the assessment has already taken, and no date has been set for the decision itself.

Price negotiation is where the outcome will be shaped. A lower agreed price could make a wider scheme affordable, while a high one would push the HSE toward the narrow group with the most severe obesity. Patients and doctors can follow the HSE pricing and reimbursement tracker, which the NCPE points to for the current status of each medicine. The decision will also be watched outside Ireland, since public payers in several countries face the same choice between broad access and a fixed budget. For more on who pays and on what terms, see our coverage desk. For list and cash prices in other markets, see the price desk.

Conclusion

Wegovy HSE reimbursement is now formally on the table after the NCPE judged the drug cost effective, but the €4.4 billion five year cost for all eligible adults means the HSE may start narrowly, if it funds the drug at all. No decision or date has been set. People paying privately should plan on doing so for now and ask their GP to watch the HSE tracker.